ID   CHK1_HUMAN              Reviewed;         476 AA.
AC   O14757; A8K934;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   02-NOV-2010, entry version 128.
DE   RecName: Full=Serine/threonine-protein kinase Chk1;
DE            EC=2.7.11.1;
GN   Name=CHEK1; Synonyms=CHK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, INTERACTION WITH CDC25A; CDC25B
RP   AND CDC25C, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, PHOSPHORYLATION,
RP   AND MUTAGENESIS OF ASP-130.
RX   MEDLINE=97426625; PubMed=9278511; DOI=10.1126/science.277.5331.1497;
RA   Sanchez Y., Wong C., Thoma R.S., Richman R., Wu Z., Piwnica-Worms H.,
RA   Elledge S.J.;
RT   "Conservation of the Chk1 checkpoint pathway in mammals: linkage of
RT   DNA damage to Cdk regulation through Cdc25.";
RL   Science 277:1497-1501(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=98044285; PubMed=9382850; DOI=10.1016/S0960-9822(06)00417-9;
RA   Flaggs G., Plug A.W., Dunks K.M., Mundt K.E., Ford J.C.,
RA   Quiggle M.R.E., Taylor E.M., Westphal C.H., Ashley T., Hoekstra M.F.,
RA   Carr A.M.;
RT   "Atm-dependent interactions of a mammalian chk1 homolog with meiotic
RT   chromosomes.";
RL   Curr. Biol. 7:977-986(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=20184068; PubMed=10717241;
RA   Semba S., Ouyang H., Han S.-Y., Kato Y., Horii A.;
RT   "Analysis of the candidate target genes for mutation in microsatellite
RT   instability-positive cancers of the colorectum, stomach, and
RT   endometrium.";
RL   Int. J. Oncol. 16:731-737(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLN-156.
RG   NIEHS SNPs program;
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Bone marrow, and Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION, AND MUTAGENESIS OF ASP-130.
RX   PubMed=10673501;
RA   Shieh S.-Y., Ahn J., Tamai K., Taya Y., Prives C.;
RT   "The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2)
RT   phosphorylate p53 at multiple DNA damage-inducible sites.";
RL   Genes Dev. 14:289-300(2000).
RN   [9]
RP   ERRATUM.
RA   Shieh S.-Y., Ahn J., Tamai K., Taya Y., Prives C.;
RL   Genes Dev. 14:750-750(2000).
RN   [10]
RP   PHOSPHORYLATION AT SER-345.
RX   MEDLINE=20317029; PubMed=10859164;
RA   Liu Q., Guntuku S., Cui X.-S., Matsuoka S., Cortez D., Tamai K.,
RA   Luo G., Carattini-Rivera S., DeMayo F., Bradley A., Donehower L.A.,
RA   Elledge S.J.;
RT   "Chk1 is an essential kinase that is regulated by Atr and required for
RT   the G(2)/M DNA damage checkpoint.";
RL   Genes Dev. 14:1448-1459(2000).
RN   [11]
RP   FUNCTION, PHOSPHORYLATION BY ATR, AND MUTAGENESIS OF ASP-130.
RX   PubMed=11535615; DOI=10.1083/jcb.200104099;
RA   Feijoo C., Hall-Jackson C., Wu R., Jenkins D., Leitch J.,
RA   Gilbert D.M., Smythe C.;
RT   "Activation of mammalian Chk1 during DNA replication arrest: a role
RT   for Chk1 in the intra-S phase checkpoint monitoring replication origin
RT   firing.";
RL   J. Cell Biol. 154:913-923(2001).
RN   [12]
RP   PHOSPHORYLATION AT SER-317 AND SER-345, AND MUTAGENESIS OF ASP-130;
RP   SER-317; SER-345; SER-357; SER-366 AND SER-468.
RX   MEDLINE=21286906; PubMed=11390642;
RX   DOI=10.1128/MCB.21.13.4129-4139.2001;
RA   Zhao H., Piwnica-Worms H.;
RT   "ATR-mediated checkpoint pathways regulate phosphorylation and
RT   activation of human Chk1.";
RL   Mol. Cell. Biol. 21:4129-4139(2001).
RN   [13]
RP   SUBSTRATE SPECIFICITY, AND MUTAGENESIS OF ASP-130.
RX   PubMed=11821419; DOI=10.1074/jbc.M111705200;
RA   O'Neill T., Giarratani L., Chen P., Iyer L., Lee C.-H., Bobiak M.,
RA   Kanai F., Zhou B.-B., Chung J.H., Rathbun G.A.;
RT   "Determination of substrate motifs for human Chk1 and hCds1/Chk2 by
RT   the oriented peptide library approach.";
RL   J. Biol. Chem. 277:16102-16115(2002).
RN   [14]
RP   ERRATUM.
RA   O'Neill T., Giarratani L., Chen P., Iyer L., Lee C.-H., Bobiak M.,
RA   Kanai F., Zhou B.-B., Chung J.H., Rathbun G.A.;
RL   J. Biol. Chem. 277:35776-35777(2002).
RN   [15]
RP   FUNCTION, PHOSPHORYLATION AT SER-317 AND SER-345, AND MUTAGENESIS OF
RP   LYS-38.
RX   PubMed=12446774; DOI=10.1128/MCB.22.24.8552-8561.2002;
RA   Heffernan T.P., Simpson D.A., Frank A.R., Heinloth A.N., Paules R.S.,
RA   Cordeiro-Stone M., Kaufmann W.K.;
RT   "An ATR- and Chk1-dependent S checkpoint inhibits replicon initiation
RT   following UVC-induced DNA damage.";
RL   Mol. Cell. Biol. 22:8552-8561(2002).
RN   [16]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH BRCA1.
RX   PubMed=11836499; DOI=10.1038/ng837;
RA   Yarden R.I., Pardo-Reoyo S., Sgagias M., Cowan K.H., Brody L.C.;
RT   "BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon
RT   DNA damage.";
RL   Nat. Genet. 30:285-289(2002).
RN   [17]
RP   FUNCTION.
RX   PubMed=12399544; DOI=10.1073/pnas.182557299;
RA   Zhao H., Watkins J.L., Piwnica-Worms H.;
RT   "Disruption of the checkpoint kinase 1/cell division cycle 25A pathway
RT   abrogates ionizing radiation-induced S and G2 checkpoints.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:14795-14800(2002).
RN   [18]
RP   FUNCTION, PHOSPHORYLATION AT SER-317 AND SER-345, AND MUTAGENESIS OF
RP   SER-317 AND SER-345.
RX   PubMed=12676583; DOI=10.1016/S1535-6108(03)00048-5;
RA   Soerensen C.S., Syljuaesen R.G., Falck J., Schroeder T.,
RA   Roennstrand L., Khanna K.K., Zhou B.-B., Bartek J., Lukas J.;
RT   "Chk1 regulates the S phase checkpoint by coupling the physiological
RT   turnover and ionizing radiation-induced accelerated proteolysis of
RT   Cdc25A.";
RL   Cancer Cell 3:247-258(2003).
RN   [19]
RP   FUNCTION, AND PHOSPHORYLATION AT SER-317.
RX   MEDLINE=22546651; PubMed=12660173; DOI=10.1093/emboj/cdg151;
RA   Groth A., Lukas J., Nigg E.A., Sillje H.H.W., Wernstedt C., Bartek J.,
RA   Hansen K.;
RT   "Human tousled like kinases are targeted by an ATM- and Chk1-dependent
RT   DNA damage checkpoint.";
RL   EMBO J. 22:1676-1687(2003).
RN   [20]
RP   FUNCTION, AND MUTAGENESIS OF ASP-130.
RX   PubMed=14681206; DOI=10.1101/gad.1157503;
RA   Jin J., Shirogane T., Xu L., Nalepa G., Qin J., Elledge S.J.,
RA   Harper J.W.;
RT   "SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A
RT   protein phosphatase.";
RL   Genes Dev. 17:3062-3074(2003).
RN   [21]
RP   PHOSPHORYLATION AT SER-317, AND MUTAGENESIS OF ASP-130; SER-317 AND
RP   SER-345.
RX   PubMed=12588868; DOI=10.1074/jbc.M210862200;
RA   Gatei M., Sloper K., Soerensen C., Syljuaesen R., Falck J., Hobson K.,
RA   Savage K., Lukas J., Zhou B.-B., Bartek J., Khanna K.K.;
RT   "Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent
RT   phosphorylation of Chk1 on ser-317 in response to ionizing
RT   radiation.";
RL   J. Biol. Chem. 278:14806-14811(2003).
RN   [22]
RP   FUNCTION, AND PHOSPHORYLATION AT SER-345.
RX   PubMed=12676925; DOI=10.1074/jbc.M300229200;
RA   Xiao Z., Chen Z., Gunasekera A.H., Sowin T.J., Rosenberg S.H.,
RA   Fesik S., Zhang H.;
RT   "Chk1 mediates S and G2 arrests through Cdc25A degradation in response
RT   to DNA-damaging agents.";
RL   J. Biol. Chem. 278:21767-21773(2003).
RN   [23]
RP   INTERACTION WITH YWHAZ AND XPO1, SUBCELLULAR LOCATION, ASSOCIATION
RP   WITH CHROMATIN, PHOSPHORYLATION AT SER-317 AND SER-345, AND
RP   MUTAGENESIS OF SER-317; PHE-344; SER-345 AND MET-353.
RX   PubMed=12676962; DOI=10.1074/jbc.M300070200;
RA   Jiang K., Pereira E., Maxfield M., Russell B., Goudelock D.M.,
RA   Sanchez Y.;
RT   "Regulation of Chk1 includes chromatin association and 14-3-3 binding
RT   following phosphorylation on ser-345.";
RL   J. Biol. Chem. 278:25207-25217(2003).
RN   [24]
RP   FUNCTION.
RX   PubMed=12759351; DOI=10.1074/jbc.M302704200;
RA   Hassepass I., Voit R., Hoffmann I.;
RT   "Phosphorylation at serine 75 is required for UV-mediated degradation
RT   of human Cdc25A phosphatase at the S-phase checkpoint.";
RL   J. Biol. Chem. 278:29824-29829(2003).
RN   [25]
RP   INTERACTION WITH CLSPN.
RX   PubMed=12766152; DOI=10.1074/jbc.M301136200;
RA   Chini C.C.S., Chen J.;
RT   "Human claspin is required for replication checkpoint control.";
RL   J. Biol. Chem. 278:30057-30062(2003).
RN   [26]
RP   FUNCTION.
RX   PubMed=14559997; DOI=10.1128/MCB.23.21.7488-7497.2003;
RA   Chen M.-S., Ryan C.E., Piwnica-Worms H.;
RT   "Chk1 kinase negatively regulates mitotic function of Cdc25A
RT   phosphatase through 14-3-3 binding.";
RL   Mol. Cell. Biol. 23:7488-7497(2003).
RN   [27]
RP   FUNCTION.
RX   PubMed=12955071; DOI=10.1038/sj.onc.1206691;
RA   Krause D.R., Jonnalagadda J.C., Gatei M.H., Sillje H.H.W., Zhou B.-B.,
RA   Nigg E.A., Khanna K.;
RT   "Suppression of tousled-like kinase activity after DNA damage or
RT   replication block requires ATM, NBS1 and Chk1.";
RL   Oncogene 22:5927-5937(2003).
RN   [28]
RP   PHOSPHORYLATION AT SER-317.
RX   PubMed=14657349; DOI=10.1073/pnas.2536810100;
RA   Wang Y., Qin J.;
RT   "MSH2 and ATR form a signaling module and regulate two branches of the
RT   damage response to DNA methylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:15387-15392(2003).
RN   [29]
RP   FUNCTION, AND PHOSPHORYLATION AT SER-345.
RX   PubMed=14988723; DOI=10.1038/sj.emboj.7600113;
RA   Pichierri P., Rosselli F.;
RT   "The DNA crosslink-induced S-phase checkpoint depends on ATR-CHK1 and
RT   ATR-NBS1-FANCD2 pathways.";
RL   EMBO J. 23:1178-1187(2004).
RN   [30]
RP   DOMAIN, MITOTIC PHOSPHORYLATION, PHOSPHORYLATION AT SER-345, AND
RP   MUTAGENESIS OF LYS-38.
RX   PubMed=14681223; DOI=10.1074/jbc.M312215200;
RA   Ng C.-P., Lee H.C., Ho C.W., Arooz T., Siu W.Y., Lau A., Poon R.Y.C.;
RT   "Differential mode of regulation of the checkpoint kinases CHK1 and
RT   CHK2 by their regulatory domains.";
RL   J. Biol. Chem. 279:8808-8819(2004).
RN   [31]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASP-130.
RX   PubMed=15311285; DOI=10.1038/ncb1165;
RA   Kraemer A., Mailand N., Lukas C., Syljuaesen R.G., Wilkinson C.J.,
RA   Nigg E.A., Bartek J., Lukas J.;
RT   "Centrosome-associated Chk1 prevents premature activation of cyclin-B-
RT   Cdk1 kinase.";
RL   Nat. Cell Biol. 6:884-891(2004).
RN   [32]
RP   INTERACTION WITH CLSPN, AND PHOSPHORYLATION AT SER-296; SER-317 AND
RP   SER-345.
RX   PubMed=15707391; DOI=10.1042/BJ20041966;
RA   Clarke C.A.L., Clarke P.R.;
RT   "DNA-dependent phosphorylation of Chk1 and claspin in a human cell-
RT   free system.";
RL   Biochem. J. 388:705-712(2005).
RN   [33]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15710331; DOI=10.1016/j.ccr.2005.01.009;
RA   Puc J., Keniry M., Li H.S., Pandita T.K., Choudhury A.D., Memeo L.,
RA   Mansukhani M., Murty V.V.V.S., Gaciong Z., Meek S.E.M.,
RA   Piwnica-Worms H., Hibshoosh H., Parsons R.;
RT   "Lack of PTEN sequesters CHK1 and initiates genetic instability.";
RL   Cancer Cell 7:193-204(2005).
RN   [34]
RP   INTERACTION WITH PPM1D, AND PHOSPHORYLATION AT SER-317 AND SER-345.
RX   PubMed=15870257; DOI=10.1101/gad.1291305;
RA   Lu X., Nannenga B., Donehower L.A.;
RT   "PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle
RT   checkpoints.";
RL   Genes Dev. 19:1162-1174(2005).
RN   [35]
RP   FUNCTION.
RX   PubMed=15659650; DOI=10.1091/mbc.E04-08-0689;
RA   Ou Y.-H., Chung P.-H., Sun T.-P., Shieh S.-Y.;
RT   "p53 C-terminal phosphorylation by CHK1 and CHK2 participates in the
RT   regulation of DNA-damage-induced C-terminal acetylation.";
RL   Mol. Biol. Cell 16:1684-1695(2005).
RN   [36]
RP   INTERACTION WITH TIMELESS.
RX   PubMed=15798197; DOI=10.1128/MCB.25.8.3109-3116.2005;
RA   Uensal-Kacmaz K., Mullen T.E., Kaufmann W.K., Sancar A.;
RT   "Coupling of human circadian and cell cycles by the timeless
RT   protein.";
RL   Mol. Cell. Biol. 25:3109-3116(2005).
RN   [37]
RP   FUNCTION, INTERACTION WITH RAD51, AND MUTAGENESIS OF SER-317 AND
RP   SER-345.
RX   PubMed=15665856; DOI=10.1038/ncb1212;
RA   Soerensen C.S., Hansen L.T., Dziegielewski J., Syljuaesen R.G.,
RA   Lundin C., Bartek J., Helleday T.;
RT   "The cell-cycle checkpoint kinase Chk1 is required for mammalian
RT   homologous recombination repair.";
RL   Nat. Cell Biol. 7:195-201(2005).
RN   [38]
RP   FUNCTION, AND PHOSPHORYLATION AT SER-345.
RX   PubMed=15650047; DOI=10.1073/pnas.0409130102;
RA   Huang X., Tran T., Zhang L., Hatcher R., Zhang P.;
RT   "DNA damage-induced mitotic catastrophe is mediated by the Chk1-
RT   dependent mitotic exit DNA damage checkpoint.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:1065-1070(2005).
RN   [39]
RP   UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-436, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Mammary cancer;
RX   PubMed=17370265; DOI=10.1002/pmic.200600410;
RA   Denis N.J., Vasilescu J., Lambert J.-P., Smith J.C., Figeys D.;
RT   "Tryptic digestion of ubiquitin standards reveals an improved strategy
RT   for identifying ubiquitinated proteins by mass spectrometry.";
RL   Proteomics 7:868-874(2007).
RN   [40]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-308 AND SER-317, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-286; SER-301; SER-308;
RP   SER-317; SER-331 AND SER-468, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [42]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-286; SER-296 AND
RP   SER-301, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [43]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [44]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-279; SER-280; SER-284
RP   AND SER-286, AND MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [45]
RP   PHOSPHORYLATION AT SER-345, UBIQUITINATION AT LYS-436, INTERACTION
RP   WITH FBXO6, AND MUTAGENESIS OF SER-345; ARG-372; ARG-376; ARG-379 AND
RP   LYS-436.
RX   PubMed=19716789; DOI=10.1016/j.molcel.2009.06.030;
RA   Zhang Y.-W., Brognard J., Coughlin C., You Z., Dolled-Filhart M.,
RA   Aslanian A., Manning G., Abraham R.T., Hunter T.;
RT   "The F box protein Fbx6 regulates Chk1 stability and cellular
RT   sensitivity to replication stress.";
RL   Mol. Cell 35:442-453(2009).
RN   [46]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-279; SER-280; SER-296
RP   AND SER-307, AND MASS SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [47]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-280 AND SER-301, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 1-289.
RX   PubMed=10761933; DOI=10.1016/S0092-8674(00)80704-7;
RA   Chen P., Luo C., Deng Y., Ryan K., Register J., Margosiak S.,
RA   Tempczyk-Russell A., Nguyen B., Myers P., Lundgren K., Kan C.-C.,
RA   O'Connor P.M.;
RT   "The 1.7 A crystal structure of human cell cycle checkpoint kinase
RT   Chk1: implications for Chk1 regulation.";
RL   Cell 100:681-692(2000).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 1-289.
RX   PubMed=12244092; DOI=10.1074/jbc.M201233200;
RA   Zhao B., Bower M.J., McDevitt P.J., Zhao H., Davis S.T.,
RA   Johanson K.O., Green S.M., Concha N.O., Zhou B.-B.S.;
RT   "Structural basis for Chk1 inhibition by UCN-01.";
RL   J. Biol. Chem. 277:46609-46615(2002).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 1-289.
RX   PubMed=15974586; DOI=10.1021/jm049022c;
RA   Foloppe N., Fisher L.M., Howes R., Kierstan P., Potter A.,
RA   Robertson A.G.S., Surgenor A.E.;
RT   "Structure-based design of novel Chk1 inhibitors: insights into
RT   hydrogen bonding and protein-ligand affinity.";
RL   J. Med. Chem. 48:4332-4345(2005).
RN   [51]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-223 AND MET-312.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Required for checkpoint mediated cell cycle arrest in
CC       response to DNA damage or the presence of unreplicated DNA. May
CC       also negatively regulate cell cycle progression during unperturbed
CC       cell cycles. Recognizes the substrate consensus sequence [R-X-X-
CC       S/T]. Binds to and phosphorylates CDC25A, CDC25B and CDC25C.
CC       Phosphorylation of CDC25A at 'Ser-178' and 'Thr-507' and
CC       phosphorylation of CDC25C at 'Ser-216' creates binding sites for
CC       14-3-3 proteins which inhibit CDC25A and CDC25C. Phosphorylation
CC       of CDC25A at 'Ser-76', 'Ser-124', 'Ser-178', 'Ser-279' and 'Ser-
CC       293' promotes proteolysis of CDC25A. Inhibition of CDC25 activity
CC       leads to increased inhibitory tyrosine phosphorylation of CDK-
CC       cyclin complexes and blocks cell cycle progression. Binds to and
CC       phosphorylates RAD51 at 'Thr-309', which may enhance the
CC       association of RAD51 with chromatin and promote DNA repair by
CC       homologous recombination. Binds to and phosphorylates TLK1 at
CC       'Ser-743', which prevents the TLK1-dependent phosphorylation of
CC       the chromatin assembly factor ASF1A. This may affect chromatin
CC       assembly during S phase or DNA repair. May also phosphorylate
CC       multiple sites within the C-terminus of TP53, which promotes
CC       activation of TP53 by acetylation and enhances suppression of
CC       cellular proliferation.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- SUBUNIT: Interacts with BRCA1, CLSPN, FBXO6, PPM1D, RAD51,
CC       TIMELESS, XPO1/CRM1 and YWHAZ/14-3-3 zeta.
CC   -!- INTERACTION:
CC       Q9NY61:AATF; NbExp=1; IntAct=EBI-974488, EBI-372428;
CC       P38398:BRCA1; NbExp=1; IntAct=EBI-974488, EBI-349905;
CC       P30304:CDC25A; NbExp=1; IntAct=EBI-974488, EBI-747671;
CC       P30307:CDC25C; NbExp=2; IntAct=EBI-974488, EBI-974439;
CC       O35280:Chek1 (xeno); NbExp=1; IntAct=EBI-974488, EBI-2553137;
CC       Q9HAW4:CLSPN; NbExp=4; IntAct=EBI-974488, EBI-1369377;
CC       P08238:HSP90AB1; NbExp=1; IntAct=EBI-974488, EBI-352572;
CC       Q9UNS1:TIMELESS; NbExp=2; IntAct=EBI-974488, EBI-2212315;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Cytoplasm, cytoskeleton,
CC       centrosome. Note=Nuclear export is mediated at least in part by
CC       XPO1/CRM1. Also localizes to the centrosome specifically during
CC       interphase, where it may protect centrosomal CDC2 kinase from
CC       inappropriate activation by cytoplasmic CDC25B.
CC   -!- TISSUE SPECIFICITY: Expressed ubiquitously with the most abundant
CC       expression in thymus, testis, small intestine and colon.
CC   -!- DOMAIN: The autoinhibitory region (AIR) inhibits the activity of
CC       the kinase domain.
CC   -!- PTM: Phosphorylated by ATR in a RAD17-dependent manner in response
CC       to ultraviolet irradiation and inhibition of DNA replication.
CC       Phosphorylated by ATM in response to ionizing irradiation. ATM and
CC       ATR can both phosphorylate Ser-317 and Ser-345 and this results in
CC       enhanced kinase activity. Phosphorylation at Ser-345 induces a
CC       change in the conformation of the protein, activates the kinase
CC       activity and is a prerequisite for interaction with FBXO6 and
CC       subsequent ubiquitination at Lys-436. Phosphorylation at Ser-345
CC       also increases binding to 14-3-3 proteins and promotes nuclear
CC       retention. Conversely, dephosphorylation at Ser-345 by PPM1D may
CC       contribute to exit from checkpoint mediated cell cycle arrest. May
CC       also be phosphorylated at Ser-280 by AKT1/PKB, which may promote
CC       mono and/or diubiquitination. Also phosphorylated at undefined
CC       residues during mitotic arrest, which results in decreased
CC       activity.
CC   -!- PTM: Ubiquitinated. Mono or diubiquitination promotes nuclear
CC       exclusion (By similarity). The activated form (phosphorylated on
CC       Ser-345) is polyubiquitinated at Lys-436 by some SCF-type E3
CC       ubiquitin ligase complex containing FBXO6 promoting its
CC       degradation. Ubiquitination of activated form is required to
CC       insure that activated CHK1 does not accumulate as cells progress
CC       through S phase, or when replication forks encounter transient
CC       impediments during normal DNA replication.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family. NIM1 subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/chek1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF016582; AAC51736.1; -; mRNA.
DR   EMBL; AF032874; AAB88852.1; -; mRNA.
DR   EMBL; AB032387; BAA84577.1; -; Genomic_DNA.
DR   EMBL; AK292549; BAF85238.1; -; mRNA.
DR   EMBL; AF527555; AAM78553.1; -; Genomic_DNA.
DR   EMBL; CH471065; EAW67644.1; -; Genomic_DNA.
DR   EMBL; BC004202; AAH04202.1; -; mRNA.
DR   EMBL; BC017575; AAH17575.1; -; mRNA.
DR   IPI; IPI00023664; -.
DR   RefSeq; NP_001107593.1; -.
DR   RefSeq; NP_001107594.1; -.
DR   RefSeq; NP_001265.2; -.
DR   UniGene; Hs.24529; -.
DR   PDB; 1IA8; X-ray; 1.70 A; A=1-289.
DR   PDB; 1NVQ; X-ray; 2.00 A; A=1-289.
DR   PDB; 1NVR; X-ray; 1.80 A; A=1-289.
DR   PDB; 1NVS; X-ray; 1.80 A; A=1-289.
DR   PDB; 1ZLT; X-ray; 1.74 A; A=1-289.
DR   PDB; 1ZYS; X-ray; 1.70 A; A=1-273.
DR   PDB; 2AYP; X-ray; 2.90 A; A=1-269.
DR   PDB; 2BR1; X-ray; 2.00 A; A=1-289.
DR   PDB; 2BRB; X-ray; 2.10 A; A=1-289.
DR   PDB; 2BRG; X-ray; 2.10 A; A=1-289.
DR   PDB; 2BRH; X-ray; 2.10 A; A=1-289.
DR   PDB; 2BRM; X-ray; 2.20 A; A=1-289.
DR   PDB; 2BRN; X-ray; 2.80 A; A=1-289.
DR   PDB; 2BRO; X-ray; 2.20 A; A=1-289.
DR   PDB; 2C3J; X-ray; 2.10 A; A=1-289.
DR   PDB; 2C3K; X-ray; 2.60 A; A=1-289.
DR   PDB; 2C3L; X-ray; 2.35 A; A=1-289.
DR   PDB; 2CGU; X-ray; 2.50 A; A=1-289.
DR   PDB; 2CGV; X-ray; 2.60 A; A=1-289.
DR   PDB; 2CGW; X-ray; 2.20 A; A=1-289.
DR   PDB; 2CGX; X-ray; 2.20 A; A=1-289.
DR   PDB; 2E9N; X-ray; 2.50 A; A=2-270.
DR   PDB; 2E9O; X-ray; 2.10 A; A=2-270.
DR   PDB; 2E9P; X-ray; 2.60 A; A=2-270.
DR   PDB; 2E9U; X-ray; 2.00 A; A=2-270.
DR   PDB; 2E9V; X-ray; 2.00 A; A/B=2-269.
DR   PDB; 2GDO; X-ray; 3.00 A; A=1-289.
DR   PDB; 2GHG; X-ray; 3.50 A; A=2-270.
DR   PDB; 2HOG; X-ray; 1.90 A; A=2-307.
DR   PDB; 2HXL; X-ray; 1.80 A; A=2-307.
DR   PDB; 2HXQ; X-ray; 2.00 A; A=2-307.
DR   PDB; 2HY0; X-ray; 1.70 A; A=2-307.
DR   PDB; 2QHM; X-ray; 2.00 A; A=1-307.
DR   PDB; 2QHN; X-ray; 1.70 A; A=1-307.
DR   PDB; 2R0U; X-ray; 1.90 A; A=1-307.
DR   PDB; 2WMQ; X-ray; 2.48 A; A=1-289.
DR   PDB; 2WMR; X-ray; 2.43 A; A=1-289.
DR   PDB; 2WMS; X-ray; 2.70 A; A=1-289.
DR   PDB; 2WMT; X-ray; 2.55 A; A=1-289.
DR   PDB; 2WMU; X-ray; 2.60 A; A=1-289.
DR   PDB; 2WMV; X-ray; 2.01 A; A=1-289.
DR   PDB; 2WMW; X-ray; 2.43 A; A=1-289.
DR   PDB; 2WMX; X-ray; 2.45 A; A=1-289.
DR   PDB; 2X8D; X-ray; 1.90 A; A=1-289.
DR   PDB; 2X8E; X-ray; 2.50 A; A=1-276.
DR   PDB; 2X8I; X-ray; 1.92 A; A=1-289.
DR   PDB; 2XEY; X-ray; 2.70 A; A=1-289.
DR   PDB; 2XEZ; X-ray; 2.25 A; A=1-289.
DR   PDB; 2XF0; X-ray; 2.40 A; A=1-289.
DR   PDB; 2YWP; X-ray; 2.90 A; A=2-270.
DR   PDB; 3F9N; X-ray; 1.90 A; A=2-307.
DR   PDB; 3JVR; X-ray; 1.76 A; A=2-272.
DR   PDB; 3JVS; X-ray; 1.90 A; A=2-272.
DR   PDBsum; 1IA8; -.
DR   PDBsum; 1NVQ; -.
DR   PDBsum; 1NVR; -.
DR   PDBsum; 1NVS; -.
DR   PDBsum; 1ZLT; -.
DR   PDBsum; 1ZYS; -.
DR   PDBsum; 2AYP; -.
DR   PDBsum; 2BR1; -.
DR   PDBsum; 2BRB; -.
DR   PDBsum; 2BRG; -.
DR   PDBsum; 2BRH; -.
DR   PDBsum; 2BRM; -.
DR   PDBsum; 2BRN; -.
DR   PDBsum; 2BRO; -.
DR   PDBsum; 2C3J; -.
DR   PDBsum; 2C3K; -.
DR   PDBsum; 2C3L; -.
DR   PDBsum; 2CGU; -.
DR   PDBsum; 2CGV; -.
DR   PDBsum; 2CGW; -.
DR   PDBsum; 2CGX; -.
DR   PDBsum; 2E9N; -.
DR   PDBsum; 2E9O; -.
DR   PDBsum; 2E9P; -.
DR   PDBsum; 2E9U; -.
DR   PDBsum; 2E9V; -.
DR   PDBsum; 2GDO; -.
DR   PDBsum; 2GHG; -.
DR   PDBsum; 2HOG; -.
DR   PDBsum; 2HXL; -.
DR   PDBsum; 2HXQ; -.
DR   PDBsum; 2HY0; -.
DR   PDBsum; 2QHM; -.
DR   PDBsum; 2QHN; -.
DR   PDBsum; 2R0U; -.
DR   PDBsum; 2WMQ; -.
DR   PDBsum; 2WMR; -.
DR   PDBsum; 2WMS; -.
DR   PDBsum; 2WMT; -.
DR   PDBsum; 2WMU; -.
DR   PDBsum; 2WMV; -.
DR   PDBsum; 2WMW; -.
DR   PDBsum; 2WMX; -.
DR   PDBsum; 2X8D; -.
DR   PDBsum; 2X8E; -.
DR   PDBsum; 2X8I; -.
DR   PDBsum; 2XEY; -.
DR   PDBsum; 2XEZ; -.
DR   PDBsum; 2XF0; -.
DR   PDBsum; 2YWP; -.
DR   PDBsum; 3F9N; -.
DR   PDBsum; 3JVR; -.
DR   PDBsum; 3JVS; -.
DR   ProteinModelPortal; O14757; -.
DR   SMR; O14757; 371-466.
DR   DIP; DIP-24182N; -.
DR   IntAct; O14757; 19.
DR   MINT; MINT-1179072; -.
DR   STRING; O14757; -.
DR   PhosphoSite; O14757; -.
DR   PRIDE; O14757; -.
DR   Ensembl; ENST00000278916; ENSP00000278916; ENSG00000149554.
DR   Ensembl; ENST00000428830; ENSP00000412504; ENSG00000149554.
DR   Ensembl; ENST00000438015; ENSP00000388648; ENSG00000149554.
DR   GeneID; 1111; -.
DR   KEGG; hsa:1111; -.
DR   CTD; 1111; -.
DR   GeneCards; GC11P125529; -.
DR   H-InvDB; HIX0201657; -.
DR   HGNC; HGNC:1925; CHEK1.
DR   HPA; CAB002049; -.
DR   MIM; 603078; gene.
DR   PharmGKB; PA110; -.
DR   eggNOG; prNOG10563; -.
DR   HOVERGEN; HBG002590; -.
DR   InParanoid; O14757; -.
DR   PhylomeDB; O14757; -.
DR   BRENDA; 2.7.11.1; 247.
DR   Pathway_Interaction_DB; circadianpathway; Circadian rhythm pathway.
DR   Reactome; REACT_1538; Cell Cycle Checkpoints.
DR   BindingDB; O14757; -.
DR   NextBio; 4608; -.
DR   ArrayExpress; O14757; -.
DR   Bgee; O14757; -.
DR   CleanEx; HS_CHEK1; -.
DR   Genevestigator; O14757; -.
DR   GermOnline; ENSG00000149554; Homo sapiens.
DR   GO; GO:0000794; C:condensed nuclear chromosome; TAS:ProtInc.
DR   GO; GO:0005815; C:microtubule organizing center; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; EXP:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; EXP:Reactome.
DR   GO; GO:0000077; P:DNA damage checkpoint; IMP:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; IMP:UniProtKB.
DR   GO; GO:0006260; P:DNA replication; EXP:Reactome.
DR   GO; GO:0007276; P:gamete generation; TAS:ProtInc.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; TAS:ProtInc.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; IEA:InterPro.
DR   GO; GO:0007131; P:reciprocal meiotic recombination; TAS:ProtInc.
DR   GO; GO:0000079; P:regulation of cyclin-dependent protein kina...; TAS:ProtInc.
DR   GO; GO:0010149; P:senescence; IDA:BHF-UCL.
DR   InterPro; IPR020636; Ca/CaM-dep_prot_kinase-like.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR015729; Ser/Thr_kin_Checkpoint-1_Hal4.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   InterPro; IPR002290; Ser/Thr_prot_kinase_dom.
DR   PANTHER; PTHR22982; Ca/CaM-dep_prot_kinase-like; 1.
DR   PANTHER; PTHR22982:SF11; Ser_thr_Chk1_Hal4; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell cycle; Complete proteome; Cytoplasm;
KW   Cytoskeleton; DNA damage; DNA repair; Isopeptide bond; Kinase;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   CHAIN         1    476       Serine/threonine-protein kinase Chk1.
FT                                /FTId=PRO_0000085848.
FT   DOMAIN        9    265       Protein kinase.
FT   NP_BIND      15     23       ATP (By similarity).
FT   REGION      391    476       Autoinhibitory region.
FT   ACT_SITE    130    130       Proton acceptor.
FT   BINDING      38     38       ATP (By similarity).
FT   MOD_RES     279    279       Phosphothreonine.
FT   MOD_RES     280    280       Phosphoserine; by PKB/AKT1 (By
FT                                similarity).
FT   MOD_RES     284    284       Phosphoserine.
FT   MOD_RES     286    286       Phosphoserine.
FT   MOD_RES     296    296       Phosphoserine.
FT   MOD_RES     301    301       Phosphoserine.
FT   MOD_RES     307    307       Phosphoserine.
FT   MOD_RES     308    308       Phosphoserine.
FT   MOD_RES     317    317       Phosphoserine; by ATM and ATR.
FT   MOD_RES     331    331       Phosphoserine.
FT   MOD_RES     345    345       Phosphoserine; by ATM and ATR.
FT   MOD_RES     468    468       Phosphoserine.
FT   CROSSLNK    436    436       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   VARIANT     156    156       R -> Q (in dbSNP:rs3731410).
FT                                /FTId=VAR_021123.
FT   VARIANT     223    223       E -> V (in dbSNP:rs35817404).
FT                                /FTId=VAR_040407.
FT   VARIANT     312    312       V -> M (in dbSNP:rs34097480).
FT                                /FTId=VAR_040408.
FT   VARIANT     471    471       V -> I (in dbSNP:rs506504).
FT                                /FTId=VAR_024571.
FT   MUTAGEN      38     38       K->R: Abolishes kinase activity.
FT   MUTAGEN     130    130       D->A: Abolishes kinase activity.
FT   MUTAGEN     317    317       S->A: Abrogates interaction with RAD51;
FT                                when associated with A-345. Reduces
FT                                phosphorylation and impairs activation by
FT                                hydroxyurea and ionizing radiation.
FT                                Abrogates nuclear retention upon
FT                                checkpoint activation. Impairs
FT                                interaction with FBXO6.
FT   MUTAGEN     317    317       S->E: Enhances interaction with RAD51;
FT                                when associated with E-345.
FT   MUTAGEN     344    344       F->A: Impairs nuclear export.
FT   MUTAGEN     345    345       S->A: Abrogates interaction with RAD51;
FT                                when associated with A-317. Reduces
FT                                phosphorylation and impairs activation by
FT                                hydroxyurea and ionizing radiation.
FT                                Impairs interaction with YWHAZ which is
FT                                required for nuclear retention after
FT                                checkpoint activation.
FT   MUTAGEN     345    345       S->E: Enhances interaction with RAD51;
FT                                when associated with E-317.
FT   MUTAGEN     353    353       M->A: Impairs nuclear export.
FT   MUTAGEN     357    357       S->A: No effect on phosphorylation
FT                                induced by hydroxyurea.
FT   MUTAGEN     366    366       S->A: No effect on phosphorylation
FT                                induced by hydroxyurea.
FT   MUTAGEN     372    372       R->E: In 3RE mutant. Disrupts the folding
FT                                and/or conformation, allowing increased
FT                                accessibility to FBXO6 component of SCF-
FT                                type E3 ubiquitin ligase complex; when
FT                                associated with E-376 and E-379.
FT   MUTAGEN     376    376       R->E: In 3RE mutant. Disrupts the folding
FT                                and/or conformation, allowing increased
FT                                accessibility to FBXO6 component of SCF-
FT                                type E3 ubiquitin ligase complex; when
FT                                associated with E-372 and E-379.
FT   MUTAGEN     379    379       R->E: In 3RE mutant. Disrupts the folding
FT                                and/or conformation, allowing increased
FT                                accessibility to FBXO6 component of SCF-
FT                                type E3 ubiquitin ligase complex; when
FT                                associated with E-372 and E-376.
FT   MUTAGEN     436    436       K->R: Enhances stability of the protein,
FT                                probably by preventing ubiquitination at
FT                                this site.
FT   MUTAGEN     468    468       S->A: No effect on phosphorylation
FT                                induced by hydroxyurea.
FT   HELIX         4      7
FT   STRAND        9     16
FT   STRAND       22     28
FT   TURN         29     31
FT   STRAND       34     41
FT   HELIX        49     61
FT   STRAND       70     74
FT   STRAND       79     85
FT   HELIX        92     95
FT   TURN         98    100
FT   HELIX       104    123
FT   HELIX       133    135
FT   STRAND      136    138
FT   STRAND      144    146
FT   HELIX       171    173
FT   HELIX       176    180
FT   HELIX       186    203
FT   STRAND      209    211
FT   HELIX       216    222
FT   HELIX       231    233
FT   HELIX       237    245
FT   TURN        250    252
FT   HELIX       256    259
FT   TURN        263    266
SQ   SEQUENCE   476 AA;  54420 MW;  0ABD0FAB67F49F67 CRC64;
     MAVPFVEDWD LVQTLGEGAY GEVQLAVNRV TEEAVAVKIV DMKRAVDCPE NIKKEICINK
     MLNHENVVKF YGHRREGNIQ YLFLEYCSGG ELFDRIEPDI GMPEPDAQRF FHQLMAGVVY
     LHGIGITHRD IKPENLLLDE RDNLKISDFG LATVFRYNNR ERLLNKMCGT LPYVAPELLK
     RREFHAEPVD VWSCGIVLTA MLAGELPWDQ PSDSCQEYSD WKEKKTYLNP WKKIDSAPLA
     LLHKILVENP SARITIPDIK KDRWYNKPLK KGAKRPRVTS GGVSESPSGF SKHIQSNLDF
     SPVNSASSEE NVKYSSSQPE PRTGLSLWDT SPSYIDKLVQ GISFSQPTCP DHMLLNSQLL
     GTPGSSQNPW QRLVKRMTRF FTKLDADKSY QCLKETCEKL GYQWKKSCMN QVTISTTDRR
     NNKLIFKVNL LEMDDKILVD FRLSKGDGLE FKRHFLKIKG KLIDIVSSQK VWLPAT
//
